PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-23.20%
Both yoy net incomes decline, with AGEN at -46.74%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.
3.49%
D&A growth well above AGEN's 2.35%. Michael Burry would suspect heavier depreciation burdens that might erode net income unless top-line follows suit.
-100.00%
Negative yoy deferred tax while AGEN stands at 4589.66%. Joel Greenblatt would consider near-term tax obligations but a possible advantage if competitor's deferrals become a burden later.
19.58%
SBC growth while AGEN is negative at -21.36%. John Neff would see competitor possibly controlling share issuance more tightly.
19.36%
Less working capital growth vs. AGEN's 135.12%, indicating potentially more efficient day-to-day cash usage. David Dodd would confirm no negative impact on revenue.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
55.56%
Lower AP growth vs. AGEN's 135.69%, indicating prompt payments. David Dodd would confirm no lost opportunity in interest-free credit if expansions are underfunded.
-124.52%
Negative yoy usage while AGEN is 117.94%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
56.31%
Some yoy increase while AGEN is negative at -122.99%. John Neff would see competitor possibly reining in intangible charges or revaluations more effectively than we do.
-16.84%
Both yoy CFO lines are negative, with AGEN at -8.57%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
100.00%
CapEx growth well above AGEN's 39.02%. Michael Burry would suspect heavier cash outlays that risk short-term free cash flow vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Investing outflow well above AGEN's 39.02%. Michael Burry sees possible short-term FCF risk unless these invests pay off quickly vs. competitor’s approach.
-594.74%
Both yoy lines negative, with AGEN at -1847.73%. Martin Whitman suspects an environment prompting net new borrowings or weaker paydowns across the niche.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.